PeptideStack
5.2kquestions
20kanswers
220users

How do I compare WWB and BCH on lead time to Norway?

Asked 9 Nov 2025Modified 6 months agoViewed 17k times
14

The particulars: WWB · BCH · Norway.

I have used one of these for a while and I am considering switching, which requires a reason.

What I care about is reproducibility, because a result I cannot repeat is not useful to me.

Which axes does this decision turn on?

vendor-comparison
vendor-comparison

Side-by-side comparison of suppliers on measurable axes - independently confirmed purity and content, lead time, cold-chain handling,…

388 questions
international-shipping
international-shipping

Cross-border movement of research material: transit lanes and their thermal profiles, tracked versus untracked, declaration accuracy, and what…

471 questions
cold-chain
cold-chain

Keeping material within a temperature window from manufacture to use: phase-change packs versus dry ice, thermal mass, transit-lane temperature…

578 questions
shareeditfollowflag
SH
askedseven_day_half31k1389 Nov 2025
7Have you ordered yet? The pre-order checks and the post-arrival checks are different lists. – b_delacroix 8 months ago
add a comment

5 Answers

Accepted answer first, then by votes
53

Accepted answer

The short version: same compound, same laboratory, same method, ideally same week — otherwise you are comparing laboratories rather than suppliers.

To compare properly: order the same compound at the same nominal strength from each supplier, submit all samples to the same laboratory in the same submission if possible, and ask for the same test set on each.

Cost per milligram, adjusted honestly

StepValueNote
Vial price, 10 mg nominal£34.00As advertised
Nominal cost per mg£3.4034 ÷ 10
Measured content9.2 mgIndependent content assay
Cost per actual mg£3.7034 ÷ 9.2
Dead-space loss, 20 draws4 %80 µL of a 2 mL fill
Cost per delivered mg£3.853.70 ÷ 0.96
First vial, with £110 assay£14.85Testing dominates a single vial

Compare documentation on a fixed checklist rather than by impression: lot specificity, method section, chromatogram availability, quantified content, water and counter-ion figures, and whether the code is on the vial.

Inter-laboratory spread on identical peptide material is routinely half a per cent to a per cent by RP-HPLC, which is the noise floor for any cross-laboratory comparison.

One laboratory, one method, one submission. Otherwise it is not a comparison.

shareimprove this answerflag
LT
answered · acceptedlane_transit60k4729 Dec 2025
5This should be linked from the help pages. – h_pergande 2 months ago
add a comment
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
57

The relevant point is that two competent laboratories disagree by half a per cent on identical material, which is larger than most of the differences people argue about.

Cost per milligram of actual peptide is the honest price comparison, which means dividing by measured content rather than by label claim.

Lead time and lane behaviour are supplier properties too and are easier to compare than analytical ones, because they need no laboratory at all.

Name the laboratory and the dates or the comparison cannot be reproduced.

edited 26 Dec 2025 by w_okoye — tightened the wording; no substantive change

shareimprove this answerflag
WO
answeredw_okoye43k1377 Dec 2025
39

Answer first: comparing suppliers is only meaningful if the comparison holds the laboratory, the method and the compound constant, and most published comparisons hold none of them.

Sample size matters. One order each is an anecdote about six vials; three orders each over a year is the beginning of a comparison.

Publish the method with the result. A comparison without the laboratory named and the submission dates given is not reproducible by anyone.

Gradient slope, column chemistry and detection wavelength all affect the reported purity figure, which is why the method section is the part that makes results comparable.

Price per milligram of measured peptide, not per milligram of label claim.

edited 26 Nov 2025 by marta_okonkwo — updated for the 2026 guidance change

shareimprove this answerflag
MO
answeredmarta_okonkwo190k25826 Nov 2025
6Worth flagging that comparing across laboratories is comparing laboratories, not suppliers. – Dr_Colm_Fitzhenry 8 months ago
7Is there a sensible order size where independent testing stops being a large surcharge? – carys_meredith 9 months ago
add a comment
24

More usefully, ratings on this site are ours alone and are deliberately not reconciled with anyone else's.

Content is the more discriminating measurement than purity for supplier comparison, because purity clusters tightly among competent suppliers and content does not.

Content assay results across the published datasets vary considerably more between suppliers than purity does, which makes content the more discriminating axis.

The caveat is that a comparison is a snapshot of the lots compared, and lots change.

Use a fixed documentation checklist rather than an impression.

shareimprove this answerflag
TM
answeredtobias_maartens171k35818 Dec 2025
18

Start by asking what you are optimising for, because cost per milligram, documentation depth and lead time do not have a common winner.

Submitting to different laboratories introduces a method difference that commonly exceeds the supplier difference. Gradient slope alone can move a reported purity figure by a per cent in either direction.

The ratings on this site are a community opinion average on a ten-point scale and are not reconciled with any other community's figures.

Comparisons drawn from different laboratories at different times are weaker evidence than most people treat them as.

Compare content, not purity. Purity clusters and content does not.

shareimprove this answerflag
TG
answeredtandem_gradient61k24820 Jan 2026
7Thank you — the checklist format makes this actionable rather than merely correct. – h_pergande 8 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.